ZYDELIG 100 MG
IDELALISIB : 100 MG · DIN 02438798 · GILEAD SCIENCES CANADA INC
Health Canada status: MARKETED
What is ZYDELIG?
ZYDELIG 100 MG contains IDELALISIB : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02438798, held by GILEAD SCIENCES CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Apr-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZYDELIG used for?
In combination with rituximab for relapsed chronic lymphocytic leukemia (CLL). Monotherapy for follicular lymphoma refractory to both rituximab and an alkylating agent (after ≥2 prior regimens).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02438798 |
|---|---|
| Brand name | ZYDELIG |
| Generic / active ingredient | IDELALISIB : 100 MG |
| Manufacturer | GILEAD SCIENCES CANADA INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EM01 IDELALISIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Apr-2015 |
| Original market date | 2015-04-21 00:00:00 |
How is it administered?
Recommended dose is 150 mg taken orally twice daily. Treatment should continue until disease progression or unacceptable toxicity. Dose modifications (100 mg BID) required for specific toxicities.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to STORAGE AND STABILITY section).
How is it supplied?
Not explicitly detailed in provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section).
Contraindications
Contraindicated in first-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) outside a clinical trial; known hypersensitivity to any components.
Warnings and precautions
Serious infections (PCP/CMV), hepatotoxicity, severe diarrhea/colitis, pneumonitis, and severe cutaneous reactions (SJS/TEN/DRESS). Prophylaxis for PCP/PJP and CMV monitoring required.
What can be used instead?
Other Canadian products sharing ATC code L01EM01 IDELALISIB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ZYDELIG | 150 MG | TABLET | GILEAD SCIENCES CANADA INC | MARKETED | DIN 02438801 |
Who else supplies IDELALISIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IDELALISIB appears in 20 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.